What's new

EMEA-001318-PIP01-12-M05

EMEA-001318-PIP01-12-M05

Feb 14, 2025 - 16:50
 0
EMEA-001318-PIP01-12-M05
EMEA-001318-PIP01-12-M05
Read More

Tags:

Previous Article

Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, Risankizumab...

Next Article

Trump EPA Trying to Claw Back $20 Billion in Green Grants — This Is Not Normal P...

Related Posts

Nilotinib product-specific bioequivalence guidance

Nilotinib product-specific bioequivalence guidance

Feb 12, 2025  0

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025  0

Orphan designation: N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d] pyrimidin-6-yl)phenyl)methacrylamide hydrochloride Treatment of biliary tract cancer, 10/11/2022 Positive

Orphan designation: N-(4-(4-amino-5-(3-fluoro-4-((4-met...

Feb 24, 2025  0